Ursula A. Matulonis

Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer

S. P. Ivy, Martin T. King, U. Matulonis, 2008 .

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

Bo Li, Aviv Regev, Mario L. Suvà, 2020, Nature Medicine.

Angiogenic mRNA and microRNA Gene Expression Signature Predicts a Novel Subtype of Serous Ovarian Cancer

Benjamin Haibe-Kains, John Quackenbush, Renee Rubio, 2012, PloS one.

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors

Aviv Regev, Mario L. Suvà, Nikhil Wagle, 2019, Nature Medicine.

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells

Young Eun Choi, Dipanjan Chowdhury, U. Matulonis, 2014, Oncotarget.

Olaparib maintenance therapy in patients with platinum‐sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy

Werner Meier, Ignace Vergote, Philipp Harter, 2016, Cancer.

Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations

Zoltan Szallasi, Yang Li, Aron C. Eklund, 2013, PloS one.